stockrow
Saturday 7 November 2026
Export UNCY’s income statement to Excel — free account
Unicycive Therapeutics, Inc.
UNCY Healthcare Biotechnology
Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022.
- EPS
- +88.5%
- Free cash flow
- +9.77%
Quarter to June 2026, against a year earlier
3.53
0.05
+1.44%
Follow UNCY
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (101.07%) | (163.14%) | (141.14%) | (102.29%) |
+8 more TTM periods Free account |
|
| (69.05%) | (86.51%) | (65.73%) | (74.93%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(66.89%) | (107.65%) | (88.25%) | (89.75%) | |
Free Cash Flow per Share |
(1.03) | (1.20) | (1.97) | (1.65) | |
Free Cash Flow |
(27.85) | (28.67) | (31.34) | (29.88) | |
Capital Expenditures |
(0.01) | (0.02) | (0.02) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(24.28%) | (31.07%) | (43.85%) | (37.27%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | (535.09) | (415.73) | (500.87) | |
Operating CF/Net income |
0.79 | 0.72 | 1.18 | 0.89 | |
Depreciation/Fixed assets |
15.61 | 13.75 | 8.67 | 7.40 | |
Capex/Depreciation |
(0.01) | (0.02) | (0.04) | (0.08) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.03) | (1.20) | (1.97) | (1.65) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026